Lantern Pharma is trading 6.9% down in after-hours trading at $1.01 after announcing a registered direct offering expected to raise approximately $4 million before expenses. - Deal: 3,669,725 shares or pre-funded warrants at $1.09 each, plus concurrent private-placement warrants for up to 3,669,725 additional shares. - Expected to close on or about September 30, 2026, subject to customary conditions. Regular-session close was $1.08, after several sharp declines in recent sessions; no after-hours volume was provided.